Core Viewpoint - The approval of "Fluralaner Chewable Tablets" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs marks a significant development for the company and its wholly-owned subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd. [1] Group 1: Product Approval - The "Fluralaner Chewable Tablets" have been approved for the treatment of ectoparasite infections in dogs, specifically targeting ticks (Rhipicephalus sanguineus) and fleas (Ctenocephalides felis, Ctenocephalides canis) [1] - The product can be utilized as part of a treatment plan for flea allergy dermatitis [1] Group 2: Market Context - Currently, the company has not been able to find information regarding the sales status and market share of similar products available in the market through public channels [1]

Core Viewpoint - The company, Pulaike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Fluralaner Chewable Tablets," which is aimed at treating external parasites in dogs [1] Group 1: Product Approval - The new veterinary drug has been officially registered and is set to be effective as of January 7, 2026, following the issuance of the New Veterinary Drug Registration Certificate [1] - The approval was granted based on the regulations outlined in the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] Group 2: Indications and Usage - The drug is indicated for the treatment of external parasites in dogs, specifically targeting ticks (Rhipicephalus sanguineus) and fleas (Ctenocephalides felis, Ctenocephalides canis) [1] - It can also be used as part of a treatment plan for flea allergy dermatitis [1]

普莱柯公告称，经农业农村部审查，批准公司及全资子公司洛阳惠中兽药有限公司等联合申报的"氟雷 拉纳咀嚼片"为新兽药，并公示核发《新兽药注册证书》。该兽药为二类，主要成分氟雷拉纳，用于治 疗犬体表蜱虫、跳蚤感染。其驱杀作用可持续12周，采用软咀嚼片制备工艺，适口性好。产品上市前还 应取得兽药产品批准文号，这对公司提升竞争力、推动宠物板块业绩增长有积极作用。 ...

格隆汇1月8日丨普莱柯(603566.SH)公布，根据《兽药管理条例》和《兽药注册办法》规定，经农业农 村部审查，批准公司及全资子公司洛阳惠中兽药有限公司等单位联合申报的"氟雷拉纳咀嚼片"为新兽 药，并于2026年1月7日公示了核发《新兽药注册证书》（中华人民共和国农业农村部公告第986号）事 项。 适应症：用于治疗犬体表的蜱虫（血红扇头蜱）、跳蚤（猫栉首蚤、犬栉首蚤）感染，可作为控制跳蚤 过敏性皮炎方案的一部分来应用。 ...

Core Viewpoint - East China Pharmaceutical's new veterinary drug for weight management in obese cats has been approved for market release, addressing a significant gap in the pet weight management sector in China [2][3] Group 1: Product Development and Market Potential - The newly approved drug can lead to an average weight loss of 9.26% in obese cats within six weeks at the recommended dosage, with over 70% of trial cats losing more than 5% of their weight [2] - The pet medical market in China has reached a scale of 80 billion yuan, making it one of the fastest-growing pet markets globally [2] - There is a notable absence of weight management solutions for pets, particularly in the area of pharmaceutical interventions, which presents a significant market opportunity [2] Group 2: Industry Challenges and Consumer Concerns - Current methods for managing pet obesity primarily involve calorie control and increased exercise, which face challenges such as long duration, hunger stress, and low compliance from pets [2] - The development of veterinary drugs often follows a "human drug/animal drug for pets" model, requiring strict regulatory frameworks to ensure safety and efficacy [2] - Pet owners express concerns about the safety of new weight management drugs, indicating a cautious approach to adopting pharmaceutical solutions despite the demand [3] Group 3: Health Implications and Recommendations - Obesity in pets can lead to serious health issues, including insulin resistance, abnormal blood lipids, hypertension, diabetes, and can directly damage joints, cardiovascular, and respiratory systems [3] - Preventive measures are emphasized as crucial, with recommendations for scientific feeding, calorie control, adequate exercise, and regular weight monitoring to prevent obesity and its complications [3]

Core Viewpoint - The company plans to invest 50 million yuan to establish a wholly-owned subsidiary in Hohhot, Inner Mongolia, aimed at enhancing production capacity and resource allocation in the veterinary medicine and feed additive sectors [1] Group 1: Investment Details - The registered capital of the new subsidiary will be 50 million yuan, with a 100% ownership stake by the company [1] - The investment is intended to leverage the advantages of the company's Phase VI project and improve cost management and operational efficiency [1] Group 2: Strategic Alignment - This initiative aligns with the company's overall development strategy and aims to expand its business layout in veterinary medicine and feed additives [1] - The establishment of the subsidiary does not require shareholder approval and is not classified as a related party transaction or a major asset restructuring [1] Group 3: Risk Management - The new subsidiary is subject to the completion of business registration, which carries certain market and operational risks [1] - The company will enhance internal controls and risk prevention mechanisms to mitigate potential risks [1]

（编辑 姚尧） 证券日报网讯 12月29日，中牧股份在互动平台回答投资者提问时表示，公司第八届董事会审议通过了 《关于收购成都中牧生物药业有限公司65%股权的议案》，收购成都中牧65%股权，进一步丰富了公司 产品结构，布局新赛道，拓展新领域，具体内容详见公司公告。公司始终以开放的心态关注行业优质合 作机会，高度重视资源整合与优势互补机会。公司将持续关注国家及行业相关政策，力争在宠物领域实 现新发展、新突破。 ...

Group 1 - The core viewpoint of the article highlights that Huisheng Biological (SZ 300871) held its third board meeting on December 23, 2025, to discuss the use of idle fundraising for cash management [1] - For the year 2024, Huisheng Biological's revenue composition is reported as 93.02% from veterinary raw materials and formulations, with the remaining 6.98% from other sources [1] Group 2 - As of the report, Huisheng Biological has a market capitalization of 4.2 billion yuan [2]

Group 1 - Company Hai Zheng Pharmaceutical (600267.SH) announced that its subsidiaries, Hai Zheng Animal Health and Yunnan Biotech, received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for two veterinary products: doxycycline hydrochloride tablets and a recombinant virus inactivated vaccine for swine fever (WH-09 strain) [1] - Doxycycline hydrochloride tablets are indicated for infections caused by Gram-positive bacteria, Gram-negative bacteria, and mycoplasma. The application for the product approval was submitted on September 13, 2025 [1] - The swine fever vaccine has an immunity period of six months and the application for its approval was submitted on October 30, 2025. Yunnan Biotech is the fourth company in China to receive approval for this vaccine [1] Group 2 - Other major manufacturers of doxycycline hydrochloride tablets include Henan Zhongmu Weifeng Biological Engineering Co., Ltd. and Anhui Kangmu Animal Health Products Co., Ltd. [1] - Other major manufacturers of the swine fever vaccine include Shandong Haili Biological Products Co., Ltd., Wuhan Keqian Biological Co., Ltd., and Anhui Dongfang Diwei Biological Products Co., Ltd. [1] - Currently, the company has not obtained specific sales revenue data for similar products from other companies through public channels [1]

Group 1 - The company has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), classified as a Category V new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The new drug is developed by Zhejiang Haizheng Animal Health Products Co., Ltd. in collaboration with seven other companies, and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug is indicated for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears, among other steroid-responsive inflammatory/allergic diseases [1] Group 2 - The registration application for the new veterinary drug was submitted in October 2024, and the product is now ready for production and market launch pending the approval of the veterinary product number [1] - Currently, the company has not been able to obtain specific sales revenue data for similar products from other companies through public channels [2]